PTC Therapeutics plans ST-920 Fabry program acquisition

PTC Therapeutics Inc. (NASDAQ: PTCT ) on Wednesday said it is expanding its rare disease portfolio through the planned acquisition of the ST-920 Fabry disease program from Sangamo Therapeutics in a competitive bankruptcy auction. 5%. • PTC Therapeutics stock is holding steady today.

What’s next for PTCT stock? PTC Therapeutics Expands Fabry Disease Pipeline With ST-920 Deal The terms include $111 million upfront and up to $100 million in contingent milestone payments based on certain regulatory approvals. A rolling BLA submission to the FDA for accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026. The application is based on evidence of meaningful favorable clinical effect on renal function and a safety and tolerability profile over 52 weeks in the Phase 1/2 STAAR study.

PTC Therapeutics is set to leverage its existing regulatory and commercial infrastructure to enhance its offerings in the Fabry therapy market with the acquisition of ST-920, a one-time administered AAV gene therapy. “This was a unique opportunity with the potential for significant return on investment without the need for any development or commercial build and without impacting our objective of reaching cash flow break-even in 2026,” said Matthew Klein, CEO of PTC Therapeutics. 08. 32, indicating a bearish trend in the short term.

The moving average convergence divergence (MACD) is above its signal line, suggesting that downside pressure is easing, although the overall trend remains uncertain. 08) — Stock is outperforming the broader market. 23) — Trading at a steep premium relative to peers. 55 at the time of publication on Thursday, according to Pro data.

Image via Shutterstock Read Also: Cathie Wood Scoops $16 Million of Broadcom Ahead of a Crucial AI Earnings Test